title: Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients.
abstract: OBJECTIVE
  The aim of this study was to examine the cumulative risk of pouchitis following restorative proctocolectomy for UC and FAP in Japanese patients, and to assess the response to medical treatment and its outcome.
  
  
  METHODS
  521 patients with UC and 117 FAP patients underwent proctocolectomy and received a J-shaped IPAA at our department of surgery. We investigated these patients using PDAI for the diagnostic criteria of pouchitis.
  
  
  RESULTS
  Pouchitis occurred in only 32 UC patients (6.1%). The cumulative risk of developing pouchitis for a UC patient was 7% at 5 years after and 12% at 10 years after surgery. The medical treatment of acute pouchitis was usually oral metronidazole (250 mg twice daily) for 2 weeks or oral ciprofloxacin (200 mg thrice daily) in patients who could not tolerate metronidazole. Single episodes of pouchitis occurred in 21 patients (65.6%) and chronic or frequent relapses of pouchitis in 11 patients (34.4%). Three patients (9.4%) required re-ileostomy. Two patients (6.3%) required pouch excision. There were no patients with complicated dysplasia.
  
  
  CONCLUSIONS
  The cumulative risk of pouchitis in Japanese UC patients is lower than that of western countries.
authors.affiliation: Second Department of Surgery, Hyogo College of Medicine, Hyogo, Japan. ikeuci2s@hyo-med.ac.jp
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ikeuchi
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nakano
authors.forename: Motoi
authors.initials: M
authors.lastname: Uchino
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Nakamura
authors.forename: Hidenori
authors.initials: H
authors.lastname: Yanagi
authors.forename: Masafumi
authors.initials: M
authors.lastname: Noda
authors.forename: Takehira
authors.initials: T
authors.lastname: Yamamura
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000601:surgery; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000601:surgery*; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D019449:Pouchitis / Q000188:drug therapy / Q000453:epidemiology*; D012008:Recurrence; D012189:Retrospective Studies; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D008795:Metronidazole; D002939:Ciprofloxacin